EUCTR2017-002473-19-FR进行中（未招募）1 期
PREDICTIVE FACTORS AND MAGNITUDE OF RESPONSE TO OMALIZUMAB AND MEPOLIZUMAB IN ALLERGIC AND EOSINOPHILIC SEVERE ASTHMA: PREDICTUMAB, AN OPEN-LABEL, CONTROLLED, RANDOMIZED MULTINATIONAL PRAGMATIC TRIA
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 364
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •oSigned informed consent form (ICF),
- •oAge >18+ years (18-90 years old) at time of signing ICF,
- •oAble to comply with the study protocol, in the investigator’s judgment,
- •oDocumented physician-diagnosed asthma ,
- •oand eligible to omalizumab and mepolizumab and who have not yet received any of these therapies. Eligibility criteria to omalizumab or mepolizumab are defined by all of these characteristics :
- •?patients with severe asthma remaining uncontrolled despite optimal, high-dose inhaled ICS therapy and LABA; (alternative add-on medication could consist of LTRA or low-dose theophylline),
- •?? 2 severe exacerbations in the previous year (as defined by requiring oral or injective corticosteroids for ?3 days or a doubled dose for cortico-dependent patients, or by emergency room visit or hospitalisation for asthma),
- •?impaired lung function (FEV1 < 80% predicted),
- •?increased serum total IgE between 76 and 700 kU/L (but a range of 30 to 1.300 kU/L also applicable in countries other than Belgium, such as France according to EMA and national rules),
- •?allergic background evidenced by specific IgE ? 0.35 kU/L and/or skin prick-test reactivity to at least one perennial allergen,
- •?and blood eosinophils ? 300/?L in at least two samples, just before initiation and during the previous year.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 145
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 219
排除标准
- •oHistory of evidence of drug/substance abuse that would pose a risk to patient safety, interfere with the conduct of study, have an impact on the study results, or affect the patient’s ability to participate in the study, in the opinion of the investigator,
- •oDifficult to treat asthma and others severe respiratory diseases,
- •oPatient already currently/actively enrolled in a clinical therapeutic trial (testing another drug); the concomitant inclusion in a Registry, which may include biosampling, is not an exclusion criterion,
- •oProtected subjects (sous tutelle or curatelle), patients who are unable to express their consent, subjects who are deprived of liberty, subjects who are hospitalized without consent, subjects who are admitted in a health-care or social institute with another aim than that of the research, inclusion in an emergency situation, patient who is subject to a court order;
- •oPregnant, post-partum or lactating women;
- •oKnown sensitivity to any of the active substances or their excipients to be administered during the study;
- •oActive malignancy or malignancy in remission over less than 5 years.
研究者
相似试验
招募中
4 期
Predictive factors and magnitude of response to omalizumab and mepolizumab in allergic and eosinophilic severe asthma: PREDICTUMAB, an open-label, controlled, randomized multinational pragmatic trial.2024-516783-29-00Cliniques Universitaires Saint-Luc340
已完成
不适用
Exploration of Predictive factors for response to Enzaltamide in bone metastasis of Prostate cancerBone metastasis of prostate cancerJPRN-UMIN000018634Department of Urology, Juntendo University Graduate School of Medicine100
招募中
不适用
Research to identify factors that predict response to enzalutamide using biopsy tissues from castration-resistant prostate cancer.castration resistant prostate cancerprostate cancer, castration-resistant, enzalutamideD064129JPRN-jRCTs051180140Akamatsu Shusuke340
已完成
不适用
A Study on Predictors of Treatment Response to ombitasvir/paritaprevir/r combination therapy in Patients with genotype 1 Chronic Hepatitis C Virus InfectioPatients with genotype 1 HCV infectionJPRN-UMIN000020299Hokkaido University260
尚未招募
4 期
Comparing efficacy of oral immunosuppressants in patients with moderate to severe psoriasisCTRI/2024/05/068034Surbhi Jain Self